Term
| What type of receptor is alpha 1 and so what is the method of signal transduction? |
|
Definition
Gq
stimulation of phospholipase C causing increase of IP3 and Ca |
|
|
Term
| Where are alpha 2 receptors? |
|
Definition
postganglionic nerve terminals
platelets
fat cells
GI tract |
|
|
Term
| What type of receptor is alpha 2 and so what is the method of signal transduction? |
|
Definition
Gi
inhibit adenylyl cyclase causing a decrease in cAMP |
|
|
Term
| What type of receptor is the beta 1 and so what is the method of signal transduction? |
|
Definition
Gs
stimulation of adenylyl cyclase and increase in cAMP |
|
|
Term
| What type of receptor is the beta 2 and so what is the method of signal transduction? |
|
Definition
Gs
stimulation of adenylyl cyclase and increase in cAMP |
|
|
Term
| What type of receptor is M2 and so what is the method of signal transduction? |
|
Definition
Gi
inhibit adenylyl cyclase causing decrease in cAMP |
|
|
Term
| What type of receptor is M3 and so what is the method of signal transduction? |
|
Definition
Gq
stimulate phospholipase C and increase IP3 and Ca |
|
|
Term
| What type of receptor is D1 and so what is the method of signal transduction |
|
Definition
Gs
stimulation of adenylyl cyclase increasing cAMP |
|
|
Term
| What type of receptor is D2 and so what is the method of signal transduction? |
|
Definition
Gi
inhibit adenylyl cyclase decreasing cAMP |
|
|
Term
| What type of receptor is H1 and so what is the method of signal transduction? |
|
Definition
Gq
stimulation of phospholipase C increasing IP3 and Ca |
|
|
Term
| What type of receptor is H2 and so what is the method of signal transduction? |
|
Definition
Gs
stimulation of adenylyl cyclase increasing cAMP |
|
|
Term
| What type of receptor is V1 and so what is the method of signal transduction? |
|
Definition
Gq
stimulation of phospholipase C increasing IP3 and Ca |
|
|
Term
| What type of receptor is V2 and so what is the method of signal transduction? |
|
Definition
Gs
stimulation of adenylyl cyclase increasing cAMP |
|
|
Term
| What type of receptor is M1 and so what is the method of signal transduction? |
|
Definition
Gq
stimulation of phospholipase C increasing IP3 and Ca |
|
|
Term
|
Definition
HAVe 1 M&M
H1, A1, V1
M1, M3 |
|
|
Term
|
Definition
|
|
Term
Hemicholinium
mechanism of action |
|
Definition
| Inhibits uptake of choline by cholinergic neurons |
|
|
Term
Vesamicol
mechanism of action |
|
Definition
Inhibits ChAT
(transporter that loads ACh vesicles) |
|
|
Term
Botulinum
mechanism of action |
|
Definition
| Inhibit release of Acetyl choline into the synapse |
|
|
Term
Metyrosine
mechanism of action |
|
Definition
| Inhibit conversion of Tyrosine to DOPA |
|
|
Term
Reserpine
mechanism of action |
|
Definition
| Inhibit loading of NE into vesicles |
|
|
Term
Guanethidine
mechanism of action |
|
Definition
| Inhibit release of NE into synapse |
|
|
Term
Amphetamine
mechanism of action
use |
|
Definition
Stimulate release of NE into synapse
Inhibit reuptake of NE
Narcolepsy, obesity, ADD |
|
|
Term
Cocaine
mechanism of action
use |
|
Definition
inhibit reuptake of NE
vasoconstriction and local anesthesia |
|
|
Term
|
Definition
|
|
Term
Bethanechol
mechanism of action
use |
|
Definition
ACh agonist resistant to AChesterase
stimulate bladder and bowel function |
|
|
Term
Carbachol
mechanism of action
use |
|
Definition
ACh agonist
Glaucoma, pupil contraction, relief of intraocular pressure |
|
|
Term
Pilocarpine
mechanism of action
use |
|
Definition
ACh agonist resistant to AChesterase
Stimulates sweat, tears, saliva. Used for open or closed angle glaucoma |
|
|
Term
Methacholine
mechanism of action
use |
|
Definition
ACh agonist
Challenge test for Asthma diagnosis |
|
|
Term
Neostigmine
mechanism of action
use |
|
Definition
Acetyl cholinesterase inhibitor with NeO CNS penetration
bladder and bowel stimulation, myasthenia gravis, reversal of neuromusular blockade |
|
|
Term
Pyridostigmine
mechanism of action
use |
|
Definition
Long acting acetylcholinesterase inhibitor with no CNS penetration
Myasthenia gravis |
|
|
Term
Edrophonium
mechanism of action
use |
|
Definition
Short acting acetyl cholinesterase inhibitor
Myasthenia gravis diagnostic test |
|
|
Term
Physostigmine
mechanism of action
use |
|
Definition
Acetylcholinesterase inhibitor with CNS penetration
Glaucoma, atropine OD |
|
|
Term
Echothiophate
mechanism of action
use |
|
Definition
Acetylcholinesterase inhibitor with CNS penetration
Glaucoma |
|
|
Term
Donepezil
mechanism of action
use |
|
Definition
Acetylcholinesterase inhibitor with CNS penetration
Alzheimer's |
|
|
Term
Pralidoxime
mechanism of action
use |
|
Definition
Acetylcholinesterase reactivator
Cholinesterase inhibitor poisoning |
|
|
Term
Atropine
mechanism of action
use |
|
Definition
Muscarinic antagonist
eye exams (dilate pupils, cycloplegia/prevent accommodation) |
|
|
Term
Homatropine
mechanism of action
use |
|
Definition
Muscarinic antagonist
eye exams (pupil dilation, cycloplegia/prevent accommodation) |
|
|
Term
Tropicamide
mechanism of action
use |
|
Definition
Muscarinic antagonist
eye exams (pupil dilation, cycloplegia/prevent accommodation) |
|
|
Term
Benztropine
mechanism of action
use |
|
Definition
Muscarininc antagonist
Parkinson's |
|
|
Term
Scopolamine
mechanism of action
use |
|
Definition
Muscarinic antagonist
Motion sickness |
|
|
Term
Ipratropium
mechanism of action
use |
|
Definition
Muscarinic antagonist
Asthma, COPD
(IPRAY I can breathe soon) |
|
|
Term
Oxybutynin
mechanism of action
use |
|
Definition
Muscarinic antagonist
reduce bladder spasms and urinary urgency |
|
|
Term
Glycopyrrolate
mechanism of action
use |
|
Definition
Muscarininc antagonist
reduce bladder spasms and urinary urgency |
|
|
Term
Methscopolamine
mechanism of action
use |
|
Definition
Muscarininc antagonist
peptic ulcers |
|
|
Term
Pirenzepine
mechanism of action
use |
|
Definition
Muscarinic antagonist
peptic ulcers |
|
|
Term
Propantheline
mechanism of action
use |
|
Definition
Muscarinic antagonist
peptic ulcers |
|
|
Term
Epinephrine
mechanism of action
use |
|
Definition
A1, A2, B1>B2 agonist
Anaphylaxis, open angle glaucoma, asthma, hypotension |
|
|
Term
Norepinephrine
mechanism of action
use |
|
Definition
A1, A2>B1 agonist
Hypotension (but decreases renal perfusion) |
|
|
Term
Isoproteronol
mechanism of action
use |
|
Definition
|
|
Term
Dopamine
mechanism of action
use |
|
Definition
D1>B2>B1>A1/A2 agonist
Shock (increases renal perfusion), heart failure, inotropic and chronotropic |
|
|
Term
Dobutamine
mechanism of action
use |
|
Definition
B1>A1/A2/B2 agonist
Heart failure, cardiac stress testing, inotropic |
|
|
Term
Phenylephrine
mechanism of action
use |
|
Definition
A1>A2 agonist
Pupil dilation, vasoconstriction, nasal decongestion |
|
|
Term
Metaproterenol
mechanism of action
use |
|
Definition
B2>B1 agonist
Acute asthma |
|
|
Term
Albuterol
mechanism of action
use |
|
Definition
B2>B1 agonist
Acute asthma |
|
|
Term
Salmeterol
mechanism of action
use |
|
Definition
B2>B1 agonist
long term asthma treatment |
|
|
Term
Terbutaline
mechanism of action
use |
|
Definition
B2>B1 agonist
Reduce premature uterine contractions |
|
|
Term
Ritodrine
mechanism of action
use |
|
Definition
B2 agonist
reduce premature uterine contractions |
|
|
Term
Ephedrine
mechanism of action
use |
|
Definition
Stimulates release of NE
Nasal decongestion, urinary incontinence, hypotension |
|
|
Term
Clonidine
mechanism of action
use |
|
Definition
CNS acting alpha 2 agonist
HTN, especially with renal disease since there is no decrease in blood flow to kidney |
|
|
Term
Methyldopa
mechanism of action
use |
|
Definition
Centrally acting alpha 2 agonist
HTN, especially with renal disease (no decrease in blood flow) or pregnancy |
|
|
Term
Phenoxybenzamine
mechanism of action
use |
|
Definition
Irreversible alpha1/2 antagonist
Pheochromocytoma pre-op because surgery releases massive amounts of catecholamines |
|
|
Term
Phentolamine
mechanism of action
use |
|
Definition
competitive alpha1/2 antagonist
give to patients on MAOI who eat tyramine |
|
|
Term
Prazosin
mechanism of action
use |
|
Definition
competitive alpha 1 antagonist
HTN, urinary retention in BPH |
|
|
Term
Terazosin
mechanism of action
use |
|
Definition
competitive alpha 1 antagonist
HTN, urinary retention in BPH |
|
|
Term
Doxazosin
mechanism of action
use |
|
Definition
competitive alpha 1 antagonist
HTN, urinary retention in BPH |
|
|
Term
Mirtazapine
mechanism of action
use
toxicity |
|
Definition
Competitive alpha 2 antagonist
Depression
sedation, increased cholesterol, increased appetite |
|
|
Term
Acebutol
mechanism of action |
|
Definition
|
|
Term
Betataxolol
mechanism of action |
|
Definition
|
|
Term
Esmolol
mechanism of action |
|
Definition
| short acting Beta 1 antagonist |
|
|
Term
Atenolol
mechanism of action |
|
Definition
|
|
Term
Metoprolol
Mechanism of action |
|
Definition
|
|
Term
Propanolol
mechanism of action |
|
Definition
| Non selective beta antagonist |
|
|
Term
Timolol
mechanism of action |
|
Definition
| Non selective beta antagonist |
|
|
Term
Nadolol
mechanism of action |
|
Definition
| Non selective beta antagonist |
|
|
Term
Pindolol
mechanism of action |
|
Definition
| Non selective beta partial agonist |
|
|
Term
Carvedilol
mechanism of action |
|
Definition
| alpha and beta antagonist |
|
|
Term
Labetalol
mechanism of action |
|
Definition
| alpha and beta antagonist |
|
|
